Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients-Reference-Cited by-同舟云学术

Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients

Published:2012-10-01 Issue:10 Volume:28 Page:1699-1708
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Biaoxue Rong¹,Shuanying Yang¹,Wei Li¹,Wei Zhang²,Zongjuan Ming¹

Affiliation:

1. Department of Respiratory Medicine, Second Affiliated Hospital, Xi’an Jiaotong University Xi’anChina

2. Department of Thoracic Surgery, Second Affiliated Hospital, Xi’an Jiaotong University Xi’anChina

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2012.728525

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wheat germ agglutinin modified mixed micelles overcome the dual barrier of mucus/enterocytes for effective oral absorption of shikonin and gefitinib;Drug Delivery and Translational Research;2024-04-24

2. Design and synthesis of gefitinib derivatives as potential drugs for cancer treatment: antiproliferative activity, molecular docking, and ADMET prediction;Letters in Drug Design & Discovery;2023-08-10

3. Tissue or blood: which is more suitable for detection of EGFR mutations in non-small cell lung cancer?;The International Journal of Biological Markers;2018-01

4. Increased Level of Annexin A1 in Bronchoalveolar Lavage Fluid as a Potential Diagnostic Indicator for Lung Cancer;The International Journal of Biological Markers;2017-01

5. Triggering of Suicidal Erythrocyte Death by Gefitinib;Cellular Physiology and Biochemistry;2017